Joseph D Tucker1,2, Juliet Iwelunmor3, Elaine Abrams4,5, Geri Donenberg6, Erin C Wilson7, Dara Blachman-Demner8, Lauren Laimon9, Babafemi O Taiwo10, Lisa M Kuhns11, Grace C John-Stewart12, Pamela Kohler13,14, Sujha Subramanian15, James Ayieko16, Titilola Gbaja-Biamila3,17, David Oladele3,17, Chisom Obiezu-Umeh3,17, Kelechi P Chima17, Emilia M Jalil18, Joana Falcao4, Oliver C Ezechi17, Bill G Kapogiannis19. 1. Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 2. Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK. 3. Behavioral Science and Health Education, College for Public Health and Social Justice, St. Louis University, St. Louis, Missouri. 4. ICAP at Columbia University Mailman School of Public Health. 5. Epidemiology Department, Columbia University Mailman School of Public Health, New York, New York. 6. Center for Dissemination and Implementation Science, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois. 7. San Francisco Department of Public Health, San Francisco, California. 8. Office of Behavioral and Social Sciences Research, National Institutes of Health, Bethesda. 9. Westat, Rockville, Maryland. 10. Department of Infectious Diseases. 11. Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 12. Departments of Global Health, Medicine, Pediatrics, and Epidemiology. 13. Department of Global Health. 14. Department of Child, Family, and Population Health Nursing, University of Washington, Seattle, Washington. 15. RTI International, Research Triangle Park, North Carolina, USA. 16. Kenya Medical Research Institute, Nairobi, Kenya. 17. Clinical Sciences Department, Nigerian Institute of Medical Research, Lagos, Nigeria. 18. National Institute of Infectious Diseases, FIOCRUZ, Rio de Janeiro, Brazil. 19. Maternal and Pediatric Infectious Diseases Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland, USA.
Abstract
OBJECTIVE: Many adolescents and young adults (AYA) have unmet HIV prevention needs. We describe the Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource Constrained Settings (PATC3H) consortium organization, transition milestones, and youth engagement strategies. The PATC3H consortium focuses on reducing HIV incidence and related health disparities among AYA. DESIGN AND METHODS: Organizational data were obtained from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and supplemented with a brief survey completed by study principal investigators. Transition from the initial phase (years 1 and 2) to the subsequent phase (years 3 and 5) was contingent on meeting prespecified milestones. We reviewed the structure and function of the research consortium, identified shared elements of transition milestones, and examined common youth engagement strategies. RESULTS: The PATC3H consortium supports eight research studies through a milestone transition mechanism. The consortium includes AYA HIV research studies in seven countries - Brazil, Kenya, Mozambique, Nigeria, South Africa, Uganda, and Zambia. The NIH request for applications required transition milestones that included early consultation with stakeholders. The transition milestones required by NIH for the eight studies included early consultation with health and policy stakeholders, pilot intervention data, and commitment from national government stakeholders. All studies provided multiple pathways for AYA engagement, including AYA advisory boards and youth-led research studies. CONCLUSION: Data suggest that requiring milestones to transition to the final phase may have facilitated health and policy stakeholder engagement and enhanced formative assessment of regulatory protocols. These data have implications for designing engaged research studies in low and middle-income countries.
OBJECTIVE: Many adolescents and young adults (AYA) have unmet HIV prevention needs. We describe the Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource Constrained Settings (PATC3H) consortium organization, transition milestones, and youth engagement strategies. The PATC3H consortium focuses on reducing HIV incidence and related health disparities among AYA. DESIGN AND METHODS: Organizational data were obtained from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and supplemented with a brief survey completed by study principal investigators. Transition from the initial phase (years 1 and 2) to the subsequent phase (years 3 and 5) was contingent on meeting prespecified milestones. We reviewed the structure and function of the research consortium, identified shared elements of transition milestones, and examined common youth engagement strategies. RESULTS: The PATC3H consortium supports eight research studies through a milestone transition mechanism. The consortium includes AYA HIV research studies in seven countries - Brazil, Kenya, Mozambique, Nigeria, South Africa, Uganda, and Zambia. The NIH request for applications required transition milestones that included early consultation with stakeholders. The transition milestones required by NIH for the eight studies included early consultation with health and policy stakeholders, pilot intervention data, and commitment from national government stakeholders. All studies provided multiple pathways for AYA engagement, including AYA advisory boards and youth-led research studies. CONCLUSION: Data suggest that requiring milestones to transition to the final phase may have facilitated health and policy stakeholder engagement and enhanced formative assessment of regulatory protocols. These data have implications for designing engaged research studies in low and middle-income countries.
Authors: George C Patton; Susan M Sawyer; John S Santelli; David A Ross; Rima Afifi; Nicholas B Allen; Monika Arora; Peter Azzopardi; Wendy Baldwin; Christopher Bonell; Ritsuko Kakuma; Elissa Kennedy; Jaqueline Mahon; Terry McGovern; Ali H Mokdad; Vikram Patel; Suzanne Petroni; Nicola Reavley; Kikelomo Taiwo; Jane Waldfogel; Dakshitha Wickremarathne; Carmen Barroso; Zulfiqar Bhutta; Adesegun O Fatusi; Amitabh Mattoo; Judith Diers; Jing Fang; Jane Ferguson; Frederick Ssewamala; Russell M Viner Journal: Lancet Date: 2016-05-09 Impact factor: 79.321
Authors: Kadija M Tahlil; Chisom Obiezu-Umeh; Titi Gbajabiamila; Juliet Iwelunmor; Oliver Ezechi; Joseph D Tucker; Ucheoma Nwaozuru; David Oladele; Adesola Z Musa; Ifeoma Idigbe; Jane Okwuzu; Agatha N David; Tajudeen A Bamidele; Collins O Airhihenbuwa; Nora E Rosenberg; Weiming Tang; Jason J Ong; Donaldson F Conserve Journal: BMC Infect Dis Date: 2021-05-31 Impact factor: 3.090
Authors: Suzanne Day; Bill G Kapogiannis; Seema K Shah; Erin C Wilson; Theodore D Ruel; Donaldson F Conserve; Ann Strode; Geri R Donenberg; Pamela Kohler; Catherine Slack; Oliver Ezechi; Joseph D Tucker Journal: Lancet HIV Date: 2020-12 Impact factor: 16.070